BGPartner Advises Memo Therapeutics in CHF 25M Funding
Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo Therapeutics’ existing investors, including Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures, and Red Alpine.
The BGPartner team assisting Memo Therapeutics in all legal and negotiation matters was led by Oliver Gnehm (Partner, pictured) and further consisted of Victoria Marty (Associate) and Barbara Meise (Associate).
MTx will use the proceeds to complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus (“BKV”) infection in kidney transplant recipients. BKV infection poses a significant threat following the transplantation procedure, with serious adverse effects on graft function and ultimately patient survival. With Phase II clinical data anticipated in 2024, the proceeds will also be used to prepare for a scale up of CMC manufacturing of AntiBKV in view of the Phase III study and potential market entry. In addition, MTx will use the funding to advance its existing antibody pipeline.
